Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The state of the IP union

Alice was the dominant topic in the AIPLA session "Addressing the Hot Topics of Today for Tomorrow's Business"

The first question that moderator Timothy Meigs of Beckton Dickinson asked the State of the IP Union Panel yesterday was: what keeps them and their clients up at night? The panel's subtitle was "Addressing the Hot Topics of Today for Tomorrow's Business," but the answer to this question was hardly a hot and fresh one: it's still Alice.

Philip Petti of USG Corporation commented: "It's sort of like we're sitting in the middle of the bus, and there's a crazy person at the wheel." Petti says he and his company feel the "reverberations" of the uncertainty brought on by Alice. From the statistics he's examined, "if our patents are tested, about 70% of them are going to fail," he said. "How do I advise my business people when I tell them we're going to put so much money into patenting that you can't even count on?"

As Microsoft's Micky Minhas sees it, Alice may be dissuading IP owners from other countries from patenting their products here, placing the US at a disadvantage. As China considers accepting patents for business methods, the US is heading "in the opposite direction," he said.

Pfizer's Adrian Looney praised Hatch-Waxman and the BPCIA for clearing the way for generics. But he also questioned whether, if the Alice decision had been handed down before the boom of generics, those pharmaceuticals that have saved many lives would even exist today. It was suggested that it is not just innovation in the biopharma space that Alice stands to inhibit. Qualcomm's Laurie Self said that funding for startups "depends on the VC community believing that you have a predictable right, an enforceable right." She added: "I really do worry that, through this constant diminishment of patent rights, you're making long-term research too risky an investment for startups."

Looney also pointed to the specificity of Hatch-Waxman litigation to one industry as a potential model for reform to 101 issues, which have been treated very inconsistently by the courts. Frustrating though the denial of cert for a number of recent 101 cases is, the panel conceded the Supreme Court has heard a number of IP cases and may still want to see the lower courts shake it out.

more from across site and ros bottom lb

More from across our site

The Asia-Pacific awards research cycle has now begun – don’t miss on this opportunity be recognised in 2023
The Supreme Court, which is hearing two IP cases this week, should limit the power of US courts to rule on foreign sales
Safety standards wouldn’t lose copyright protection when named in law, so long as they were accessible for free online
In-house tech sources say Amgen v Sanofi has the potential to stifle their prosecution and litigation strategies if SCOTUS’s decision is too broad
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
The Federal Circuit said tech firms can challenge the way the USPTO implemented Fintiv, but that won’t mean much for practitioners, say counsel
The England and Wales High Court handed down one of the most hotly anticipated FRAND rulings for some time
Funders discuss different IP portfolio funding options and how they decide whether to offer preferential terms and pricing
The issue of the Unified Patent Court’s third central division needs resolving before IP owners can fully embrace Europe’s new era
Foreign firms and lawyers, including IP practitioners, can now practise in India after years of talk and no action